San Francisco-based Amprion, headed by CEO Russ Lebovitz, MD/PhD has developed a proprietary technology called Protein Misfolding Cyclic Amplification (PMCA), using CSF and plasma alpha-Synuclein (Î±S) to aid in the diagnosis of Parkinson’s disease. Their device has received a Breakthrough Device designation from U.S. FDA.
On Oct. 6th, 2021 Amprion has announced the commercial rollout of its innovative SYNTap Biomarker Test, a first-in-class laboratory-developed test (LDT) for accurate and reliable detection of Î±-synuclein aggregates, a hallmark in various brain diseases. The SYNTap Test aids in diagnosing synucleinopathies such as Parkinsonâ€™s, Lewy Body Dementia, and Multiple System Atrophy (MSA).
In addition, the novel test helps distinguish underlying synucleinopathies in other neurodegenerative conditions, such as Alzheimerâ€™s. The SYNTap Test identifies prion-like Î±-synuclein aggregates using a few drops of CSF (about one hundred microliters), confirming the presence of progressive brain disease. Test results are intended to accompany other clinical and diagnostic findings for patient case management.